Limits...
Cost and effectiveness of omega-3 fatty acid supplementation in Chinese ICU patients receiving parenteral nutrition.

Wu GH, Gao J, Ji CY, Pradelli L, Xi QL, Zhuang QL - Clinicoecon Outcomes Res (2015)

Bottom Line: The model predicted that omega-3 PUFA-enriched emulsion (Omegaven(®) 10% fish oil emulsion) would dominate standard lipid emulsions, with better clinical outcomes and lower overall health care costs (mean savings ~10,000 RMB), mainly as a result of faster recovery and shorter hospital stay (by ~6.5 days).The external validation process confirmed the reliability of the model predictions.Omega-3 PUFA-enriched lipid emulsions improved clinical outcome and decreased overall costs in Chinese ICU patients requiring PN.

View Article: PubMed Central - PubMed

Affiliation: Department of General Surgery, Fudan University, Shanghai, People's Republic of China.

ABSTRACT

Background and objectives: Clinical evidence supports the use of omega-3 polyunsaturated fatty acid (PUFA)-enriched lipid emulsions in place of standard lipid emulsions in parenteral nutrition (PN) for intensive care unit (ICU) patients, but uptake may be limited by higher costs. We compared clinical and economic outcomes for these two types of lipid emulsion in the Chinese ICU setting.

Methods: We developed a pharmacoeconomic discrete event simulation model, based on efficacy data from an international meta-analysis and patient characteristics, resource consumption, and unit costs from a Chinese institutional setting. Probabilistic sensitivity analyses were undertaken to assess the effects of uncertainty around input parameters. Model predictive validity was assessed by comparing results with data observed in a patient subset not used in the modeling.

Results: The model predicted that omega-3 PUFA-enriched emulsion (Omegaven(®) 10% fish oil emulsion) would dominate standard lipid emulsions, with better clinical outcomes and lower overall health care costs (mean savings ~10,000 RMB), mainly as a result of faster recovery and shorter hospital stay (by ~6.5 days). The external validation process confirmed the reliability of the model predictions.

Conclusion: Omega-3 PUFA-enriched lipid emulsions improved clinical outcome and decreased overall costs in Chinese ICU patients requiring PN.

No MeSH data available.


Model validation: observed versus predicted hospital length of stay for the two treatment arms.Note: Min–max lines represent the 95% CI of predicted values.Abbreviations: CI, confidence interval; LOS, length of stay.
© Copyright Policy
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4492652&req=5

f3-ceor-7-369: Model validation: observed versus predicted hospital length of stay for the two treatment arms.Note: Min–max lines represent the 95% CI of predicted values.Abbreviations: CI, confidence interval; LOS, length of stay.

Mentions: The results of the comparison are presented in Figures 3 and 4. The model appears to have good predictive validity in the Chinese ICU setting. All observations are reasonably close to the mean of model predictions and fall well within the 95% confidence interval (CI) of the values predicted by the PSA. It appears that the estimated LOS differences are a bit conservative, at least when compared to this particular population of patients in the Zhongshan Hospital, whereas the observed cost difference is slightly lower than the predicted mean. In any case, the main findings of the simulation and of the observation coincide, indicating improved patient outcomes at reduced mean costs.


Cost and effectiveness of omega-3 fatty acid supplementation in Chinese ICU patients receiving parenteral nutrition.

Wu GH, Gao J, Ji CY, Pradelli L, Xi QL, Zhuang QL - Clinicoecon Outcomes Res (2015)

Model validation: observed versus predicted hospital length of stay for the two treatment arms.Note: Min–max lines represent the 95% CI of predicted values.Abbreviations: CI, confidence interval; LOS, length of stay.
© Copyright Policy
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4492652&req=5

f3-ceor-7-369: Model validation: observed versus predicted hospital length of stay for the two treatment arms.Note: Min–max lines represent the 95% CI of predicted values.Abbreviations: CI, confidence interval; LOS, length of stay.
Mentions: The results of the comparison are presented in Figures 3 and 4. The model appears to have good predictive validity in the Chinese ICU setting. All observations are reasonably close to the mean of model predictions and fall well within the 95% confidence interval (CI) of the values predicted by the PSA. It appears that the estimated LOS differences are a bit conservative, at least when compared to this particular population of patients in the Zhongshan Hospital, whereas the observed cost difference is slightly lower than the predicted mean. In any case, the main findings of the simulation and of the observation coincide, indicating improved patient outcomes at reduced mean costs.

Bottom Line: The model predicted that omega-3 PUFA-enriched emulsion (Omegaven(®) 10% fish oil emulsion) would dominate standard lipid emulsions, with better clinical outcomes and lower overall health care costs (mean savings ~10,000 RMB), mainly as a result of faster recovery and shorter hospital stay (by ~6.5 days).The external validation process confirmed the reliability of the model predictions.Omega-3 PUFA-enriched lipid emulsions improved clinical outcome and decreased overall costs in Chinese ICU patients requiring PN.

View Article: PubMed Central - PubMed

Affiliation: Department of General Surgery, Fudan University, Shanghai, People's Republic of China.

ABSTRACT

Background and objectives: Clinical evidence supports the use of omega-3 polyunsaturated fatty acid (PUFA)-enriched lipid emulsions in place of standard lipid emulsions in parenteral nutrition (PN) for intensive care unit (ICU) patients, but uptake may be limited by higher costs. We compared clinical and economic outcomes for these two types of lipid emulsion in the Chinese ICU setting.

Methods: We developed a pharmacoeconomic discrete event simulation model, based on efficacy data from an international meta-analysis and patient characteristics, resource consumption, and unit costs from a Chinese institutional setting. Probabilistic sensitivity analyses were undertaken to assess the effects of uncertainty around input parameters. Model predictive validity was assessed by comparing results with data observed in a patient subset not used in the modeling.

Results: The model predicted that omega-3 PUFA-enriched emulsion (Omegaven(®) 10% fish oil emulsion) would dominate standard lipid emulsions, with better clinical outcomes and lower overall health care costs (mean savings ~10,000 RMB), mainly as a result of faster recovery and shorter hospital stay (by ~6.5 days). The external validation process confirmed the reliability of the model predictions.

Conclusion: Omega-3 PUFA-enriched lipid emulsions improved clinical outcome and decreased overall costs in Chinese ICU patients requiring PN.

No MeSH data available.